Athens, Greece – 26 May 2019: Drug therapy for patients with stable heart failure can be simplified by stopping diuretics, according to late breaking results from the ReBIC-1 trial presented today1 at Heart Failure 2019, a scientific congress of the European Society of Cardiology (ESC).
“Heart failure patients have many pills to take for their heart failure and for comorbidities such as diabetes and hypertension,” said principal investigator Dr Luis E. Rohde, of the Federal University of Rio Grande do Sul, Porto Alegre, Brazil. “Withdrawing one drug when it is no longer necessary should make it easier to take the ones that are needed.”
“Patients don’t like using diuretics because they feel they have to stay at home to use the bathroom and they get cramps,” he added. “Patients would welcome being able to stop this medication.”
Diuretics are commonly prescribed for symptom relief in patients with heart failure. The drugs get rid of the excess fluids (congestion) which cause shortness of breath, swollen legs, coughing, and weight gain. Once the symptoms have resolved, patients are maintained on a low dose due to concerns that symptoms may return. Observational research has shown that long-term diuretic use is associated with a worse prognosis.
The ReBIC-1 trial examined the safety and tolerability of withdrawing the diuretic furosemide in outpatients with stable chronic heart failure. The trial was conducted by the Brazilian Research Network in Heart Failure (ReBIC), which includes 11 tertiary care university hospitals in Brazil.
Eligible criteria were: no or mild symptoms (defined as New York Heart Association functional class I to II), reduced left ventricular ejection fraction (45% or below), no heart failure-related hospital admission within the last six months, and receiving low-dose furosemide (40 to 80 mg per day) for at least six months.
A total of 188 patients were randomly allocated to maintain or withdraw furosemide. Patients in the withdrawal group received a placebo pill. Both patients and investigators were blinded to the treatment allocation. The trial had two coprimary outcomes: 1) patient reported dyspnoea using a visual analogue scale at four time points across 90 days; and 2) the proportion of patients maintained without additional diuretics during the 90-day follow-up (on top of the randomly allocated diuretic or placebo).
There was no difference between groups in the self-perception of dyspnoea during the 90-day follow-up period. Also, 72 patients (75.3%) in the withdrawal group and 78 patients (83.9%) in the maintenance group were free of furosemide reuse during follow-up (p=0.16).
Senior author Dr Andréia Biolo, of the Federal University of Rio Grande do Sul, who presented the results in Athens, said: “The results show that patients with stable heart failure who stop diuretics do not have more dyspnoea than those who continue taking the drug. Withdrawal also does not lead to increased reuse of diuretics – around 20% of patients in both groups needed a top-up, presumably for symptom relief.”
Dr Rohde said the findings indicate that diuretics can be safely discontinued in heart failure patients meeting the trial’s eligibility criteria. “Most patients we see in the heart failure outpatient clinic fulfil the trial criteria and could benefit from this strategy,” he said.
No extra follow-up is needed for patients who quit taking diuretics, noted Dr Biolo. “Patients can be followed-up in the usual way,” she said. “And, as we do now, patients should be educated to seek medical help if they become breathless, get oedema, or have sudden weight gain which indicates fluid retention.”
###
Authors: ESC Press Office
Tel: +33 (0)4 8987 2499
Mobile: +33 (0)7 8531 2036
Email: press@escardio.org
Follow us on Twitter @ESCardioNews
The hashtag for Heart Failure 2019 and the World Congress on Acute Heart Failure is #heartfailure2019.
Funding: Brazilian National Council for Scientific and Technological Development (CNPq, Brazil).
Disclosures: None.
References and notes
1 The abstract ‘Furosemide Withdrawal in Stable Chronic Outpatients with Heart Failure: a Double-blind, Multicenter, Randomized Trial’ will be presented during the session Late breaking trial II – Chronic heart failure on Sunday 26 May at 08:30 to 10:00 EEST in the Trianti lecture room.
About Heart Failure and the World Congress on Acute Heart Failure
Heart Failure and the World Congress on Acute Heart Failure are annual congresses of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
About the Heart Failure Association
The Heart Failure Association (HFA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
Information for journalists attending Heart Failure 2019
Heart Failure 2019 and the World Congress on Acute Heart Failure will be held 25 to 28 May at the Megaron Athens International Conference Centre in Athens, Greece. Explore the scientific programme.
- To register on-site please bring a valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related, or referring to a previous ESC Event).
- Press registration is not available to industry or its public relations representatives, event management, marketing or communications representatives.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.